Company Profile
CorMedix Inc. Stock Price, News & Catalysts
- Ticker:
- CRMD
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
7.67 USD (+1.72%)
Close
Last updated: August 17, 2026
641M USD
Market cap
Why the stock is moving
As of Aug 17, 2026, CRMD closed up 1.72% at $7.67. No new same-company headline was identified in the current news window.
Company overview
Institutional Anti-Infective Company
CorMedix Therapeutics develops and commercializes products used in hospitals, dialysis clinics, infusion centers, and other institutional settings of care.
DefenCath
DefenCath is a taurolidine and heparin catheter-lock solution used to reduce catheter-related bloodstream infections in adult hemodialysis patients with central venous catheters. It is the company’s largest commercial product.
Acquired Melinta Portfolio
The Melinta acquisition added marketed anti-infectives, including REZZAYO, and expanded CorMedix’s hospital-focused commercial organization.
Late-Stage Expansion Programs
CorMedix is developing REZZAYO for prophylaxis of invasive fungal disease after allogeneic stem-cell transplantation and DefenCath for patients receiving total parenteral nutrition.
Future catalysts
- Submission of an sNDA for REZZAYO prophylaxis in the third quarter of 2026.
- Potential FDA action on the REZZAYO sNDA in the first half of 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of CorMedix Inc. (CRMD)?
CorMedix Inc. (CRMD) most recently closed at 7.67 USD, a +1.72% move versus the previous session.
What is the market cap of CorMedix Inc. (CRMD)?
CorMedix Inc. currently has a market capitalization of 641M USD on BioPharmSignal.
What does CorMedix Inc. do?
Institutional Anti-Infective Company CorMedix Therapeutics develops and commercializes products used in hospitals, dialysis clinics, infusion centers, and other institutional settings of care. DefenCath DefenCath is a taurolidine and heparin catheter-lock solution used to reduce catheter-related bloodstream infections in adult hemodialysis patients with...
On which exchange is CRMD stock listed?
CorMedix Inc. (CRMD) is associated with NASDAQ, United States, Biopharma.
What is Institutional?
Institutional Anti-Infective Company CorMedix Therapeutics develops and commercializes products used in hospitals, dialysis clinics, infusion centers, and other institutional settings of care.
Which conditions is CorMedix Inc. targeting with Institutional?
Institutional Anti-Infective Company CorMedix Therapeutics develops and commercializes products used in hospitals, dialysis clinics, infusion centers, and other institutional settings of care. DefenCath DefenCath is a taurolidine and heparin catheter-lock solution used to reduce catheter-related bloodstream infections in adult hemodialysis patients with...
How does CorMedix Inc. describe recent progress with Institutional?
Submission of an sNDA for REZZAYO prophylaxis in the third quarter of 2026. Potential FDA action on the REZZAYO sNDA in the first half of 2027.
What is Anti-Infective?
Institutional Anti-Infective Company CorMedix Therapeutics develops and commercializes products used in hospitals, dialysis clinics, infusion centers, and other institutional settings of care.